gs 5734 ebola virus disease evd viral proteases (Gilead Sciences)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Gilead Sciences gs 5734 ebola virus disease evd viral proteases
Gs 5734 Ebola Virus Disease Evd Viral Proteases, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 99/100, based on 15620 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ebola+virus+disease+evd/VEKLURY/10__1097_slash_js9__0000000000004053-107-20-19
Average 99 stars, based on 15620 article reviews

gs 5734 ebola virus disease evd viral proteases - by Bioz Stars, 2026-10

99/100 stars

Images

Activity Assay:

Article Title: The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observational and case studies reported safety outcomes: an updated systematic review and meta-analysis
Article Snippet: .. Remdesivir (GS-5734) is a novel experimental nucleotide analogue that was invented by Gilead life sciences for the treatment of Ebola virus disease (EVD) in the year 2016. , Remdesivir has shown activity against SARS-CoV-2 in vitro – and related coronaviruses, including severe acute respiratory syndrome (SARS-CoV-1) and the Middle East respiratory syndrome–related coronavirus (MERS-CoV) as well, both in vitro and in animal studies. ..

In Vitro:

Virus:

Article Title: An open-label, randomized, single intravenous dosing study to investigate the effect of fixed dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR)
Article Snippet: .. In a rhesus monkey model of Ebola virus disease (EVD), once daily administration of remdesivir at a dose of 10mg/kg resulted in profound suppression of Ebola virus (EBOV) replication and protected 100% of infected animals against lethal disease, ameliorating clinical disease signs and pathophysiological markers (7–9). .. However, an interim analysis of the PALM clinical trial that was comparing four therapeutics for the Zaire Ebolavirus outbreak (mab114, REGN-EB3, remdesivir and ZMapp) decided to stop the study and randomise all remaining patients to either one of two monoclonal antibody-based therapies mAb114 or REGN-EB3.

Infection:

Article Title: An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR)
Article Snippet: .. In a rhesus monkey model of Ebola virus disease (EVD), once daily administration of remdesivir at a dose of 10mg/kg resulted in profound suppression of Ebola virus (EBOV) replication and protected 100% of infected animals against lethal disease, ameliorating clinical disease signs and pathophysiological markers [ – ]. .. However, an interim analysis of the PALM clinical trial that was comparing four therapeutics for the Zaire Ebolavirus outbreak (mab114, REGN-EB3, remdesivir, and ZMapp) decided to stop the study and randomize all remaining patients to either one of two monoclonal antibody-based therapies mAb114 or REGN-EB3.

Review